FGI-103 is an antiviral drug developed as a potential treatment for the filoviruses Ebola virus and Marburg virus.

In tests on mice FGI-103 was effective against both Ebola and Marburg viruses when administered up to 48 hours after infection.

The mechanism of action of FGI-103 has however not yet been established, as it was found not to be acting by any of the known mechanisms used by similar antiviral drugs.

[1][2][3] This antiinfective drug article is a stub.

You can help Wikipedia by expanding it.